Home
>
US Stocks
>
Cytosorbents Corp
Cytosorbents Corp
CTSO

Cytosorbents Corp (CTSO)

$5.840.17%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$5.8
Today Low/High$5.8 / $5.86
52 Week Low/High$5.75 / $11.68
Market Cap$253.71M

Company Details

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 110,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.
OrganisationCytosorbents Corp
HeadquatersMonmouth Junction, New Jersey, US
Employees195
IndustryHealth Technology
CEOPhillip Chan

Discover more

Frequently Asked Questions

What is Cytosorbents Corp (CTSO) share price today?

Can Indians buy Cytosorbents Corp (CTSO) shares?

How can I buy Cytosorbents Corp (CTSO) shares from India?

Can Fractional shares of Cytosorbents Corp (CTSO) be purchased?

What are the documents required to start investing in Cytosorbents Corp (CTSO) stocks?

We are a SEBI registered investement advisor